Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for FDC
Revenue projections for FDC



Financial Ratios:

currentRatio 2.98300
forwardPE 0.00000
debtToEquity 0.85200
earningsGrowth -0.60500
revenueGrowth -0.07900
grossMargins 0.65678
operatingMargins 0.03936
trailingEps 13.86000
forwardEps 23.30000

FDC's current ratio being 2.983 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, FDC can easily cover its immediate liabilities, reflecting solid financial health.
FDC's low earnings and revenue growth indicate potential profit shrinkage. This suggests that the company's financial performance may be weakening, raising concerns about its future profitability and overall business outlook.
FDC's negative gross and operating margins indicate that the company is currently unprofitable at both the production and operational levels. This suggests significant challenges in managing costs and generating revenue, which could impact its overall financial health.
With FDC's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in FDC's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Recommendation changes over time:

Recommendations trend for FDC
Recommendations trend for FDC


A recent buy bias from analysts toward FDC indicates strong confidence in the stock's future performance. This could encourage investors to park their money in FDC, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.